BioSpace News Archive

The Lung Cancer Research Foundation® announced the awardees of its 2021 Scientific Grant Program during its Evening of Innovation Virtual Celebration, emceed by Dave Bjork, who created and hosts the podcast The Research Evangelist.

“Most notably, we made important progress in our Phase 1 clinical trial with NVG-291 in the third quarter of 2021,” stated Paul Brennan, NervGen’s President & CEO.

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by PharmaEssentia to be a specialty pharmacy partner for BESREMi (ropeginterferon alfa-2b-njft) which is now approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with polycythemia vera.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today initiation of OASIS-HAE, the registrational study in the donidalorsen (formerly IONIS-PKK-LRx) Phase 3 clinical program.

Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1st and 2nd, 2021. Jack Kenny, Chief Executive Officer, pre-recorded a fireside chat on Tuesday, November 16, 2021.

ncellDx’s Chronic COVID Treatment Center (CCTC) (www.covidlonghaulers.com) and ARISE™ MD Integrative Medicine & Surgery announced today a new partnership to evaluate CCR5 antagonists and statins as a potential therapeutic treatment approach for chronic COVID, also known as long COVID or post-acute sequelae of COVID-19 (PASC).

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed Bridget Martell, MA, M.D., to the Company’s board of directors.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,312,500 shares at the public offering price of $40.00 per share.

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders, today announced that Cory Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the Piper Sandler 33rd Annual Healthcare Conference.

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference.